Medrio's Early Adopter Program offers three tiers of discounted access to clinical trial software, with Level 2 participants ...
XTX501 is a novel PD-1/masked IL-2 bispecific that has the potential to become a foundational backbone regimen for solid tumors. Anticipate reporting initial Phase 1 data in the f ...
CS2009, an Innovative PD-1/VEGF/CTLA-4 trispecific antibody, demonstrates a differentiated profile through synergistic triple ...
Chinese cancer research is making its mark: new antibody-drug conjugates and bispecific antibodies improve survival in ...
At King Faisal Specialist Hospital and Research Centre (KFSH), nurses play an integral role in patient safety and continuous improvement and take part in clinical decision-making. As essential members ...
Replacing a suburban house-turned-clinic in Perth, a new dental healthcare building by SPH Architecture and Interiors goes ...
A qualitative study of 36 newly qualified nurses in Ghana's Western Region found that clinical rotation brought both ...
A Journal of Translational Medicine review outlines how mRNA-encoded antibodies, bispecific constructs, and transient CAR ...
InSilico Medicine Cayman TopCo announced preliminary promising first-in-human Phase I clinical trial data for ISM6331, an investigational oral pan-TEAD inhibitor designed using Chemistry42 generative ...
Inclusive design must be about more than just meeting a baseline. Recent specialist projects demonstrate how prioritising ...
CERo Therapeutics Holdings, Inc., (OTCQB: CERO) ('CERo” or the 'Company”), an innovative cellular immunotherapy company advancing engineered T cell therapeutics designed to engage phagocytic ...
CERo Therapeutics Holdings, Inc. (OTCQB: CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company advancing engineered T cell therapeutics designed to engage phagocytic mechanisms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results